Cos (e.g., Cos-7, Etc.) Patents (Class 435/365)
  • Patent number: 10376539
    Abstract: Disclosed are methods of inhibiting progression, stabilizing and reversing amyotrophic lateral sclerosis and neuromuscular degenerative diseases including spinal muscular atrophy, by administration of xenon, or noble gas compositions at a sufficient frequency and concentration to evoke anti-inflammatory, immunomodulatory, and regenerative processes in a patient in need of therapy. In one embodiment, xenon is administered as a pharmaceutical preparation at a concentration of 5 to 90% by volume, more preferably for certain embodiments, at 5 to 30% by volume, wherein said pharmaceutical preparation additionally contains oxygen, argon, nitrogen and/or air. In other embodiments argon is utilized together, or as a replacement for xenon. Furthermore, the use of xenon and/or other noble gas combinations are disclosed for augmentation of therapies that augment endogenous regenerative cells.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: August 13, 2019
    Assignee: Nobilis Therapeutics, Inc.
    Inventors: Vlad Bogin, Thomas Ichim, Santosh Kesari
  • Patent number: 9952216
    Abstract: Herein are described a set of novel specific human enhancers for specific forebrain cell types used to study and select for human neural progenitor cells. This approach enables the ability to generate interneurons from human ES, iPS and iN cells, making them available for human transplantation and for molecular/cellular analyzes. These approaches are also directly applicable to generating other neuronal cell types, such as cortical and striatal projection neurons, which have implications for many human diseases.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: April 24, 2018
    Assignee: The Regents of the University of California
    Inventors: Axel Visel, John L. R. Rubenstein, Ying-Jiun (Jasmine) Chen, Len A. Pennacchio, Daniel Vogt, Cory Nicholas, Arnold Kriegstein
  • Patent number: 9486494
    Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 8, 2016
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventor: Kunwar Shailubhai
  • Publication number: 20150147349
    Abstract: This invention relates to compositions and methods for eliciting an immune response against a parasite of the genus Plasmodium in a mammal.
    Type: Application
    Filed: February 15, 2013
    Publication date: May 28, 2015
    Inventors: Timothy A. Springer, Chafen Lu, Gaojie Song, Adem Koksal
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Publication number: 20150139953
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 21, 2015
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Publication number: 20150133379
    Abstract: The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein. The fusion protein significantly enhances the skin penetration and skin retention of the physiologically active protein while maintaining or enhancing the ability of the physiologically active protein to synthesize a material showing physiologically active effects. Thus, it can be widely used as an active ingredient in functional cosmetic compositions and pharmaceutical compositions for external skin use.
    Type: Application
    Filed: April 30, 2014
    Publication date: May 14, 2015
    Inventors: Seol Hoon Lee, Sang Hwa Lee, Nae Gyu Kang, Eu Gene Hur
  • Publication number: 20150132330
    Abstract: Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use.
    Type: Application
    Filed: September 19, 2012
    Publication date: May 14, 2015
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Natalie Pica, Dirk Eggink, Rafael A. Medina-Silva, Rong Hai
  • Publication number: 20150125893
    Abstract: The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one transporter protein that changes three-dimensional conformation upon specifically transporting its substrate. The transporter protein may be a nitrate transporter, a peptide transporter, or a hormone transporter. The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one mechanosensitive ion channel protein. The invention also provides for methods of using the fusion proteins of the present invention and nucleic acids encoding the fusion proteins.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Wolf B. Frommer, Cheng-Hsun Ho
  • Publication number: 20150111222
    Abstract: The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.
    Type: Application
    Filed: August 8, 2012
    Publication date: April 23, 2015
    Applicant: HOWARD hUGHES MEDICAL INSTITUTE
    Inventors: Jonathan Marvin, Loren Looger, Richard T. Lee, Eric Schreiter
  • Publication number: 20150110825
    Abstract: The present invention provides nanoparticles and compositions of various constructs that combine meta-stable viral proteins (e.g., RSV F protein) and self-assembling molecules (e.g., ferritin, HSPs) such that the pre-fusion conformational state of these key viral proteins is preserved (and locked) along with the protein self-assembling into a polyhedral shape, thereby creating nanoparticles that are effective vaccine agents. The invention also provides nanoparticles comprising a viral fusion protein, or fragment or variant thereof, and a self-assembling molecule, and immunogenic and vaccine compositions including the same.
    Type: Application
    Filed: September 24, 2014
    Publication date: April 23, 2015
    Inventors: Ram SASISEKHARAN, Aditya RAGURAM, Vidya SUBRAMANIAN
  • Publication number: 20150111233
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Satoshi INOUYE, Junichi SATO
  • Publication number: 20150104450
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Application
    Filed: March 11, 2013
    Publication date: April 16, 2015
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • Publication number: 20150105315
    Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique Industrielle
    Inventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
  • Publication number: 20150098956
    Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
  • Publication number: 20150094450
    Abstract: The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of STAT3 and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases.
    Type: Application
    Filed: February 27, 2013
    Publication date: April 2, 2015
    Applicants: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC), KOREA BASIC SCIENCE INSTITUTE
    Inventors: Hak-Sung Kim, Joong-Jae Lee, Jung Min Choi, Eun-Kyeong Jo, Chul-Su Yang, Hae-Kap Cheong, Hyun Jung Kim
  • Publication number: 20150094271
    Abstract: A leucine zipper variant, a polynucleotide encoding the leucine zipper variant, a method of preparing a leucine zipper variant, a method of inhibiting HDM2- and/or HDMX using the leucine zipper variant, and a method of the prevention and/or treatment of cancer using the leucine zipper variant.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 2, 2015
    Inventors: Jung-Hoon Lee, Eunji Kang, Hye Yoon Kang, Dongkyu Shin, Jae Il Lee, Jieun Han, Jung Min Lee
  • Publication number: 20150087604
    Abstract: The present invention relates to a polypeptide that is capable of inhibiting transcription and expression of fatty acid synthase (FAS) and the polynucleotides encoding therefor, as well as the use thereof. Specifically, the present invention relates to a polypeptide that can inhibit the transcription and expression of FAS at the molecular level, the cellular level and in vivo, and can therefore prevent the overexpression of FAS. Said polypeptide and related peptidomimetics, including functional fragments or functional varieties thereof, and the genes encoding therefor, can be widely used in preventing and treating tumors such as liver cancer, and diseases closely related to the metabolism of fatty acid synthase, such as fatty liver and obesity.
    Type: Application
    Filed: April 16, 2012
    Publication date: March 26, 2015
    Inventors: Xiaodong Zhang, Lihong Ye
  • Publication number: 20150087596
    Abstract: The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, methods of making and using the foregoing, and methods of alleviating pain with peptide inhibitors of Nav1.7.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Inventors: William Eckert, Mack Flinspach, Michael Hunter, Yi Liu, Robert Neff, Alan Wickenden, Alan Gibbs
  • Publication number: 20150072383
    Abstract: The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents. The present disclosure provides engineered polypeptides having transaminase activity, polynucleotides encoding the polypeptides, methods of the making the polypeptides, and methods of using the polypeptides for the biocatalytic conversion of ketone substrates to amine products. The present enzymes have been engineered to have one or more residue differences as compared to the amino acid sequence of the naturally occurring transaminase of Vibrio fluvialis. In particular, the transaminases of the present disclosure have been engineered for efficient formation of chiral tryptamine derivatives from its corresponding prochiral ketone substrates.
    Type: Application
    Filed: March 22, 2013
    Publication date: March 12, 2015
    Inventors: Jovana Nazor, Derek Smith, Michael Crowe, Shiwei Song, Steven J. Collier
  • Publication number: 20150071858
    Abstract: The present invention relates to the use of p11 as a drug target as well as a tool for the diagnosis, treatment and development of p11/5-HT receptor related disorders. The invention further relates to p11 knock-out animals as well as p11 transgenic animals and their use as models for the development of novel psychotherapeutic agents, and to methods of diagnosis, prophylaxis and treatment of p11/5-HT receptor related disorders.
    Type: Application
    Filed: August 5, 2014
    Publication date: March 12, 2015
    Inventors: Per SVENNINGSSON, Paul GREENGARD
  • Publication number: 20150072353
    Abstract: Analyte sensors, methods for producing and using analyte sensors, methods of detecting and/or measuring analyte activity, detecting pH change, and/or, controlling the concentration of an analyte in a system, are disclosed. Embodiments of the analyte sensors according to the disclosure can provide an accurate and convenient method for characterizing analyte activity, detecting pH change, controlling the concentration of an analyte in a system, and the like, in both in vivo and in vitro environments, in particular in living cell imaging.
    Type: Application
    Filed: August 21, 2014
    Publication date: March 12, 2015
    Inventors: Jenny Jie Yang, Shen Tang
  • Publication number: 20150071883
    Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.
    Type: Application
    Filed: September 10, 2014
    Publication date: March 12, 2015
    Inventor: Peter Cameron Colosi
  • Publication number: 20150065560
    Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: March 5, 2015
    Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik
  • Patent number: 8961977
    Abstract: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: February 24, 2015
    Assignee: University of Rochester
    Inventors: Stephen Dewhurst, Mark A. Sullivan
  • Publication number: 20150050264
    Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.
    Type: Application
    Filed: September 7, 2012
    Publication date: February 19, 2015
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Denis VIVIEN, Jerome PARCQ, Denis VIVIEN, Jerome PARCQ
  • Publication number: 20150037872
    Abstract: The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 ? from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.
    Type: Application
    Filed: October 15, 2014
    Publication date: February 5, 2015
    Inventors: Erwin Ludo Roggen, Steffen Ernst, Allan Svendsen, Esben Peter Friis, Claus Von Der Osten
  • Publication number: 20150038675
    Abstract: The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride.
    Type: Application
    Filed: February 12, 2013
    Publication date: February 5, 2015
    Inventors: Yoichi Kumada, Michimasa Kishimoto, Takeru Otsuka
  • Publication number: 20150037284
    Abstract: The present invention relates to a novel Listeria bacteriophage designated ProCC P825. In particular, the present invention relates to the endolysin PlyP825 encoded by the novel phage ProCC P825 and uses of the novel endolysin PlyP825 for controlling Listeria contamination and infection.
    Type: Application
    Filed: May 29, 2012
    Publication date: February 5, 2015
    Applicant: DSM IP ASSETS B.V.
    Inventors: Holger Grallert, Julia Lorenz, Anna Scherzinger
  • Publication number: 20150023995
    Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.
    Type: Application
    Filed: July 25, 2014
    Publication date: January 22, 2015
    Applicant: TAKEDA VACCINES, INC.
    Inventors: Charles RICHARDSON, Robert F. BARGATZE, Joel HAYNES, Bryan STEADMAN
  • Publication number: 20150018522
    Abstract: Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 15, 2015
    Applicant: The United States of America, as represented by the Secretary, Department of Health & Human Servic
    Inventors: Pradman K. Qasba, Elizabeth Boeggeman, Boopathy Ramakrishnan
  • Publication number: 20150020221
    Abstract: The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes.
    Type: Application
    Filed: October 5, 2012
    Publication date: January 15, 2015
    Inventors: Margaret A. Shipp, Qingsheng Yan
  • Publication number: 20150017695
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 15, 2015
    Inventors: Jack Liang, Stephane J. Jenne, Emily Mundorff, Charlene Ching, John M. Gruber, Anke Krebber, Gjalt W. Huisman
  • Publication number: 20150010532
    Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 8, 2015
    Inventor: Wayne K. Herber
  • Publication number: 20150005177
    Abstract: Provided here are new methods to identify specific families of mammalian odorant receptors for odorants or aroma, particularly indole and skatole malodors and their use in assays that may be used to discover compounds that modulate (blocking, enhancing, masking or mimicking compounds) their activity. Orphan mouse odorant receptors are identified from olfactory sensory neurons that respond to target compounds. The resulting receptors as well as their human counterparts can be screened in assays against test compounds to confirm their identity as odorant or aroma receptors, particularly malodor receptors and subsequently discover for example modulators that inhibit the perception of the malodor in humans.
    Type: Application
    Filed: June 28, 2014
    Publication date: January 1, 2015
    Applicant: FIRMENICH SA
    Inventors: Patrick PFISTER, Matthew E. ROGERS, Khalid Jerod PARRIS
  • Publication number: 20140377407
    Abstract: This invention relates to a novel alpha-amylase, a process for its preparation and the use of the amylase. The invention relates to a newly identified polynucleotide sequence from Alicyclobacillus pohliae comprising a gene that encodes the novel alpha-amylase enzyme. The invention features the full length coding sequence of the novel gene as well as the amino acid sequence of the full-length functional protein of the gene. The invention also relates to methods of using these proteins in industrial processes, for example in food industry, such as the baking industry. Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these proteins and cells.
    Type: Application
    Filed: January 29, 2013
    Publication date: December 25, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventor: Lucie Parenicova
  • Publication number: 20140377800
    Abstract: The present invention relates to methods of optimization of a protein coding sequences for expression in a given host cell. The methods apply genetic algorithms to optimise single codon fitness and/or codon pair fitness sequences coding for a predetermined amino acid sequence. In the algorithm generation of new sequence variants and subsequent selection of fitter variants is reiterated until the variant coding sequences reach a minimum value for single codon fitness and/or codon pair fitness. The invention also relates to a computer comprising a processor and memory, the processor being arranged to read from and write into the memory, the memory comprising data and instructions arranged to provide the processor with the capacity to perform the genetic algorithms for optimisation of single codon fitness and/or codon pair fitness.
    Type: Application
    Filed: May 20, 2014
    Publication date: December 25, 2014
    Inventors: Johannes Andries ROUBOS, Noel Nicolaas Maria Elisabeth VAN PEIJ
  • Patent number: 8911776
    Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: December 16, 2014
    Inventor: Claresa Levetan
  • Publication number: 20140356346
    Abstract: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
    Type: Application
    Filed: May 15, 2014
    Publication date: December 4, 2014
    Applicant: CSL Behring GmbH
    Inventors: Thomas WEIMER, Stefan SCHULTE, Ulrich KRONTHALER, Wiegand LANG, Uwe LIEBING, Wilfried WORMSBÄCHER
  • Publication number: 20140357564
    Abstract: The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.
    Type: Application
    Filed: February 14, 2013
    Publication date: December 4, 2014
    Inventors: Stefan Schulte, Thomas Weimer, Kay Hofmann
  • Publication number: 20140356944
    Abstract: The present disclosure provides engineered transaminase polypeptides having improved properties as compared to naturally occurring transaminases including the ability of converting the substrate, 3?-hydroxyacetophenone to (S)-3-(1-aminoethyl)-phenol in enantiomeric excess and high percentage conversion. Also provided are polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to synthesize (S)-3-(1-aminoethyl)-phenol and related compounds useful in the production of active pharmaceutical ingredients.
    Type: Application
    Filed: August 19, 2014
    Publication date: December 4, 2014
    Inventors: Fabien Louis Cabirol, Anupam Gohel, Seong Ho Oh, Derek J. Smith, Brian Wong, James J. Lalonde
  • Publication number: 20140356871
    Abstract: The disclosure relates to the field of human genetics, particularly the field of peripheral neuropathy, particularly inherited peripheral neuropathy. Specifically, the disclosure relates to methods and materials to detect hereditary peripheral neuropathy, more particularly autosomal recessive Charcot-Marie-Tooth disease.
    Type: Application
    Filed: January 10, 2013
    Publication date: December 4, 2014
    Applicant: VIB VZW
    Inventors: Albena Jordanova, Magdalena Zimon, Jonathan Baets, Peter De Jonghe
  • Publication number: 20140356347
    Abstract: The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer.
    Type: Application
    Filed: September 21, 2012
    Publication date: December 4, 2014
    Inventors: Stefan Barth, Sonja Schiffer, Grit Hehmann-Titt
  • Publication number: 20140348817
    Abstract: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.
    Type: Application
    Filed: August 14, 2014
    Publication date: November 27, 2014
    Inventors: Ping Jiang, H. Michael Shepard, Lei Huang
  • Publication number: 20140342401
    Abstract: The present invention relates to a transfected mammalian host cell whose ability to secrete a foreign protein has been enhanced by using a foreign gene expression vector having a promoter derived from a human gene, and a method for producing the foreign protein using the host cell. A method for enhancing the production of a foreign protein to be used in a pharmaceutical protein product in a host cell such as a cultured mammalian cell is provided. A promoter derived from a human gene having a promoter activity higher than that of a cytomegalovirus (CMV) promoter in a host cell such as a cultured mammalian cell is provided.
    Type: Application
    Filed: May 28, 2014
    Publication date: November 20, 2014
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Kenji Murakami
  • Publication number: 20140342412
    Abstract: The present disclosure relates to transaminase polypeptides capable of aminating a dicarbonyl substrate, and polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 20, 2014
    Applicant: CODEXIS, INC.
    Inventors: Fabien Cabirol, Haibin Chen, Anupam Gohel, Paulina Salim, Derek Smith, Jacob Janey, Birgit Kosjek, Weng Lin Tang, Helen Hsieh, Son Pham
  • Publication number: 20140335053
    Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
    Type: Application
    Filed: May 22, 2014
    Publication date: November 13, 2014
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
  • Publication number: 20140336236
    Abstract: Novel ALK and NTRK1 fusion molecules and uses are disclosed.
    Type: Application
    Filed: April 21, 2014
    Publication date: November 13, 2014
    Applicant: FOUNDATION MEDICINE, INC.
    Inventors: Maureen T. Cronin, Doron Lipson, Roman Yelensky
  • Publication number: 20140328875
    Abstract: Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 6, 2014
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
  • Publication number: 20140329250
    Abstract: The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc.
    Type: Application
    Filed: May 30, 2014
    Publication date: November 6, 2014
    Inventors: Satoshi INOUYE, Yuiko SAHARA